1 completed, 1 recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Recruiting 1 |
Follow Cortisol Excess: new trials by email Literature Review of Cortisol Excess trials Research Report on Cortisol Excess
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D) clofutriben, Placebo - Type 2 Diabetes, Cortisol Excess | Phase 2 | Recruiting | Sparrow Pharmaceuticals | 1500 | 2025-11-29 | 2026-10-06 |
| SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome SPI-62, Placebo - Cushing's Syndrome I, Cushing Disease Due to Increased ACTH Secretion | Phase 2 | Completed | Sparrow Pharmaceuticals | 26 | 2022-09-01 | 2025-10-08 |
ACTH Syndrome, Ectopic (2) · Cushing Syndrome (2) · Diabetes Mellitus, Type 2 (1) · Pituitary ACTH Hypersecretion (1)
Adrenal Gland Diseases (2) · Adrenocortical Hyperfunction (2) · Endocrine System Diseases (2) · Neoplasms (2) · Paraneoplastic Endocrine Syndromes (2) · Paraneoplastic Syndromes (2) · Brain Diseases (1) · Central Nervous System Diseases (1) · Diabetes Mellitus (1) · Glucose Metabolism Disorders (1) · Hyperpituitarism (1) · Hypothalamic Diseases (1) · Metabolic Diseases (1) · Nervous System Diseases (1) · Nutritional and Metabolic Diseases (1)
ASP3662 (1)
United States (2) · Bulgaria (1) · Romania (1)